HOME >> MEDICINE >> NEWS
Novel drugs help solve Gleevec resistance

ove to be safe, and the study can move seamlessly from Phase I into Phase II. "No patient is ever 'stuck' at a lower, potentially ineffective dose," says Giles, who helped design the protocol. "Everyone keeps moving up until we find the best dose that is both safe and active." Doses from 50 milligrams to 1,200 milligrams have been tested so far. "This kind of study is in the best interest of patients because it gives us the power and the numbers to quickly find the dose that can work best," he says.

The study is funded by Novartis, which manufacturers both AMN107 and Gleevec.

Both drugs have "tight" mechanism of action

Gleevec, as well as its two new companions, reduces the activity of an abnormal tyrosine kinase enzyme that leads to uncontrolled cell growth. Both CML and Philadelphia-positive ALL is caused by the swapping of genetic material in bone marrow stem cells between chromosome 9 and 22, producing an abnormality called the Philadelphia chromosome (named for the city from where the first patient in whom it was seen resided).

Specifically, a fusing of a piece of chromosome 9 that contains part of the ABL gene with a piece of chromosome 22 that contains part of the BCR gene forms the new cancer causing gene, BCR-ABL. This oncogene produces a tyrosine kinase that turns on multiple signals that tell the cells to grow and divide in an uncontrolled manner leading to overt leukemia. Gleevec binds to the abnormal enzyme (Bcr-Abl) and shuts down its activity, often leading to the death of the leukemia cell.

AMN107 is up to 30 times more potent than Gleevec because it was designed to more efficiently bind to the enzyme, Giles says. "Through molecular, chemical and crystallography studies, we now know the detailed structure of the enzyme, which allowed the development of the better-fitting drug AMN107," he says. "This both increases the effectiveness of the agent and perhaps reduces the potential of developing resistanc
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-794-1584
University of Texas M. D. Anderson Cancer Center
5-Dec-2004


Page: 1 2 3 4 5

Related medicine news :

1. Novel therapy tested in mice could chase away cat allergies
2. Novel antibiotic shows promise in shortening treatment duration of tuberculosis
3. Novel p53 gene-based therapy boosts immune system and reduces tumor size
4. Novel imaging technique shows abnormal brain anatomy in children with ADHD
5. Novel drug-antidote strategy provides greater control of drug action
6. Novel imaging technique shows lymph nodes, metastases in breast cancer without surgery
7. Novel delivery method for nutrients wins Kaye Innovation Award for Hebrew university students
8. Novel vitamin discovery offers clues for cancer chemotherapy and lipid disorders
9. Novel findings about neovessel formation
10. Novel MRI technique provides clear images of blood flow
11. Novelty-seeking teens may be more easily influenced by tobacco advertisements

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/17/2019)... , ... July 17, 2019 , ... ... and administrators of critical access hospitals. , The men and women included on ... overseen hospital expansions, mergers and EHR implementations as well as the construction of ...
(Date:7/17/2019)... , ... July 17, 2019 , ... ... providers working with the ICD-10 coding set, is launching an exclusive educational webcast ... (CEUs) at no additional charge, officials announced this week. , The ICD10monitor ...
(Date:7/17/2019)... ... July 17, 2019 , ... This past Saturday, Monarch Dental® ... Everyone Foundation . Over 50 underserved patients were welcomed at the Mesquite office to ... celebrating the summer season. Individuals were referred to the event through local nonprofit organizations ...
(Date:7/17/2019)... (PRWEB) , ... July 17, 2019 , ... A new ... Journal of the American Medical Association (JAMA), shows for the first time ... deaths in the state. Sepsis is the body’s extreme response to infection. It kills ...
(Date:7/17/2019)... ... ... A medical home care program found that having a single accessible point ... seniors. While this may not sound surprising, a recent two year medical home pilot ... (BRI) uncovered several surprising outcomes based on a simple formatted healthcare delivery system. ...
Breaking Medicine News(10 mins):
(Date:7/19/2019)... ... July 19, 2019 , ... The new studies will ... non-invasive transdermal (over-the-skin) technology, which is the leader in the field of microcirculation ... evidence obtained by Circularity over the past six years. The clinical work has ...
(Date:7/19/2019)... ... , ... Robinson Pharma, Inc., is proud to announce that it has achieved ... Safe Quality Food (SQF) Institute using an accredited certification process and RPI is now ... 8. , The SQF Certification program is trusted by buyers around the world. It ...
(Date:7/18/2019)... ... July 18, 2019 , ... Fresh blueberries are now found ... Collection of homegrown edible berry bushes. , These ornamental berry shrubs, which took ... to any garden or on the patio in containers, not out of sight in ...
Breaking Medicine Technology:
Cached News: